Related Experiment Videos
The effect of interobserver differences in post-implant prostate CT image interpretation on dosimetric parameters
Ben H Han1, Kent Wallner, Gregory Merrick
1Department of Radiation Oncology, University of Washington, Seattle, Washington, USA.
Medical Physics
|July 11, 2003
Summary
Interobserver variability in CT scan interpretation for prostate brachytherapy exists, impacting dosimetric parameter evaluation. V100 and treatment margins show more consistency than D90, suggesting their utility as quality indices.
Area of Science:
- Radiology
- Medical Physics
- Oncology
Background:
- Prostate brachytherapy utilizes CT scans for treatment planning and dosimetry.
- Interobserver variability in CT interpretation can affect the accuracy of dosimetric calculations.
- Standardized protocols are needed to minimize discrepancies in image interpretation.
Purpose of the Study:
- To assess interobserver variability in CT scan interpretation for prostate brachytherapy.
- To correlate interpretation differences with clinically relevant dosimetric parameters.
- To evaluate the suitability of dosimetric parameters as interinstitutional quality indices.
Main Methods:
- Twenty patients undergoing I-125 or Pd-103 brachytherapy were retrospectively analyzed.
- Four physician investigators independently outlined the prostate on post-implant CT scans.
- Dosimetric parameters including V100 and D90 were calculated and compared.
Main Results:
- Moderate interobserver variability was observed in CT volume determination (median SD: 17%).
- Variability was highest in prostate length, width, and thickness, impacting treatment margins.
- A significant percentage of implants were deemed inadequate based on D90 (24%) versus V100 (14%).
Conclusions:
- CT-based dosimetry provides useful, reproducible information despite interpretation variability.
- V100 and treatment margins are less susceptible to interobserver variability than D90.
- V100 and treatment margins may serve as more reliable interinstitutional quality indices for prostate brachytherapy.